Company Profile
Sector
HealthcareIndustry
BiotechnologyEmployees
81Website
apnimed.comCountry
United StatesExchange
NASDAQCambridge, Massachusetts
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets.
It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.